{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:53:09Z","timestamp":1761706389375},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.transproceed.2018.03.010","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T13:53:20Z","timestamp":1520603600000},"page":"4099-4101","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Case Report of Immunosuppressant Medication\u2012Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol\u2012Conjugated Uricase Enzyme Pegloticase"],"prefix":"10.1016","volume":"50","author":[{"given":"B.","family":"Freyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.03.010_bib1","doi-asserted-by":"crossref","first-page":"e27233","DOI":"10.5812\/numonthly.7(3)2015.27233","article-title":"Associations between hyperuricemia and chronic kidney disease: a review","volume":"7","author":"Prasad Sah","year":"2015","journal-title":"Nephrourol Mon"},{"key":"10.1016\/j.transproceed.2018.03.010_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2009.109884","article-title":"Menopause, postmenopausal hormone use and risk of incident gout","volume":"69","author":"Hak","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.transproceed.2018.03.010_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-010-0154-6","article-title":"Quality of care in patients with gout: why is management suboptimal and what can be done about it?","volume":"13","author":"Edwards","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.transproceed.2018.03.010_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/BOR.0b013e3282f4eff5","article-title":"Refractory gout: what is it and what to do about it?","volume":"20","author":"Fels","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.transproceed.2018.03.010_bib5","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels\u00a0following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.transproceed.2018.03.010_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.transproceed.2018.03.010_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-0500-7-54","article-title":"Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials","volume":"7","author":"Yood","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.transproceed.2018.03.010_bib8","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.transproceed.2018.03.010_bib9","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.transproceed.2018.03.010_bib10","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.transproceed.2018.03.010_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.transproceed.2018.03.010_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.03.010_bib13","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2165\/00003495-200565180-00004","article-title":"Gout in solid organ transplantation: a challenging clinical problem","volume":"65","author":"Stamp","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2018.03.010_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.transproceed.2018.03.010_bib15","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518302343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518302343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T12:21:30Z","timestamp":1570882890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518302343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0041134518302343"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.03.010","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Case Report of Immunosuppressant Medication\u2012Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol\u2012Conjugated Uricase Enzyme Pegloticase","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}